5 Key Takeaways

• 1

  The Artera breast model is an FDA-cleared AI tool that integrates digital pathology and clinical variables for breast cancer risk stratification.

• 2

  In a study of over 300 early-stage breast cancer patients, the Artera AI tool outperformed the 21-gene recurrence score in prognostic value.

• 3

  Patients with concordantly low scores from both Artera and Oncotype had no distant recurrences at 10 years, indicating strong prognostic accuracy.

• 4

  Discordant scores showed a significant difference in 10-year distant metastasis rates, with 20% recurrence in patients with Oncotype low and Artera high.

• 5

  The study suggests that the Artera AI tool provides additional prognostic information beyond traditional recurrence score categories.